Braveheart Bio, Inc.

Report interim analysis results from LIONHEART-HCM Phase 3 trial

Deadline not yet reached (430 days left)

Announced: 8 Sep 2026
Due: 31 Dec 2027

Deadline
Met
Late
Not met
Today

What the company said

“We continue to expect results from an interim analysis from LIONHEART-HCM in the second half of 2027”

SourceBraveheart Bio, Inc. Form 8-K press release, 2026-09-08
Archived copyWayback Machine snapshot
FilingSEC filing index
Deadline as statedthe second half of 2027
Deadline used31 Dec 2027, the last day of the stated period
TypeProduct
Permanent referenceKI-C-2026-BRVE-000448
Cite as https://keptindex.org/c/KI-C-2026-BRVE-000448/ — this address never changes.

What we found

The deadline has not passed yet, so there is nothing to check. We look for evidence starting 30 days after 31 Dec 2027.

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Clinical readout late
Indicative materiality: High rules
Action: Report
Language: Expected (“expects”, “plans”)

Tell me what happens

This deadline has not been settled yet. We check 30 days after it passes. Get an email when we record the outcome.

Alert me when this resolves

How this entry was checked

Commitment recordedRecorded from the company's filing.
OutcomeNot yet assessed. Nothing is judged before the deadline.

Are you Braveheart Bio, Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.

Report an error in this entry Reference: KI-C-2026-BRVE-000448 · Corrections policy